Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus.

Article Details

Citation

Copy to clipboard

Lamos EM, Younk LM, Davis SN

Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus.

Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):763-75. doi: 10.1517/17425255.2013.791282. Epub 2013 Apr 17.

PubMed ID

23590413 [ View in PubMed

]

Abstract

INTRODUCTION: Canagliflozin is an orally administered sodium glucose cotransporter 2 inhibitor proposed for the treatment of type 2 diabetes. Canagliflozin improves glycemic control in an insulin-independent fashion through inhibition of glucose reuptake in the kidney. AREAS COVERED: This article reviews the available data on the pharmacodynamics, the pharmacokinetics and metabolism, and the efficacy and safety of canagliflozin. Relevant articles were identified via PubMed using the search term canagliflozin with no date restriction. The authors also discuss the abstracts from canagliflozin studies presented at large diabetes conferences. EXPERT OPINION: Canagliflozin offers a relatively modest reduction in HbA1c, FPG, and PPG. It has a low incidence of hypoglycemia and a reduction in body weight. Dose adjustment may be recommended in the elderly, those on loop diuretics, and those with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m(2) if there are concerns or symptoms of volume-related side effects. Issues remain with observed increases in low-density lipoprotein cholesterol (LDL-C) and the odds of heart attack and stroke. Canagliflozin offers a novel mechanism of action, a modest glycemic control, and a favorable side-effect profile. It was approved by the US Food and Drug Administration in April 2013 and is undergoing evaluation by the European Medicines Agency.

DrugBank Data that Cites this Article

Drugs

Canagliflozin

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Canagliflozin	Sodium/glucose cotransporter 2	Protein	Humans	Yes	Inhibitor	Details

Drug Carriers

Drug	Carrier	Kind	Organism	Pharmacological Action	Actions
Canagliflozin	Alpha-1-acid glycoprotein 1	Protein	Humans	Unknown	Substrate	Details